186 related articles for article (PubMed ID: 31643137)
1. Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan.
Feng LY; Wada K; Chung H; Han E; Li JH
Kaohsiung J Med Sci; 2020 Feb; 36(2):135-142. PubMed ID: 31643137
[TBL] [Abstract][Full Text] [Related]
2. New psychoactive substances in Taiwan: challenges and strategies.
Feng LY; Li JH
Curr Opin Psychiatry; 2020 Jul; 33(4):306-311. PubMed ID: 32167950
[TBL] [Abstract][Full Text] [Related]
3. Comparison of illegal drug use pattern in Taiwan and Korea from 2006 to 2014.
Feng LY; Yu WJ; Chang WT; Han E; Chung H; Li JH
Subst Abuse Treat Prev Policy; 2016 Sep; 11(1):34. PubMed ID: 27663984
[TBL] [Abstract][Full Text] [Related]
4. New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.
Yu WJ; Cottler L; Li JH
J Food Drug Anal; 2021 Mar; 29(1):168-181. PubMed ID: 35696229
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
[TBL] [Abstract][Full Text] [Related]
6. Comparison of controlled drugs and new psychoactive substances (NPS) regulations in East and Southeast Asia.
Lin OA; Chuang PJ; Tseng YJ
Regul Toxicol Pharmacol; 2023 Feb; 138():105338. PubMed ID: 36642324
[TBL] [Abstract][Full Text] [Related]
7. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
Zaami S
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
[TBL] [Abstract][Full Text] [Related]
8. Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.
Neicun J; Steenhuizen M; van Kessel R; Yang JC; Negri A; Czabanowska K; Corazza O; Roman-Urrestarazu A
PLoS One; 2019; 14(6):e0218011. PubMed ID: 31242225
[TBL] [Abstract][Full Text] [Related]
9. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
Rychert M; Wilkins C
Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
[TBL] [Abstract][Full Text] [Related]
10. An overview of recent developments in the analytical detection of new psychoactive substances (NPSs).
Smith JP; Sutcliffe OB; Banks CE
Analyst; 2015 Aug; 140(15):4932-48. PubMed ID: 26031385
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the nutrient-based standards for school lunches among South Korea, Japan, and Taiwan.
Kim M; Abe S; Zhang C; Kim S; Choi J; Hernandez E; Nozue M; Yoon J
Asia Pac J Clin Nutr; 2017 Jan; 26(1):160-168. PubMed ID: 28049276
[TBL] [Abstract][Full Text] [Related]
12. New psychoactive substances legislation in Ireland - Perspectives from academia.
Kavanagh PV; Power JD
Drug Test Anal; 2014; 6(7-8):884-91. PubMed ID: 24478277
[TBL] [Abstract][Full Text] [Related]
13. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
Reuter P; Pardo B
Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
[TBL] [Abstract][Full Text] [Related]
14. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
Rychert M; Wilkins C
Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
[TBL] [Abstract][Full Text] [Related]
15. Emergence, Diversity, and Control of New Psychoactive Substances: A Global Perspective.
Tettey JNA; Crean C; Ifeagwu SC; Raithelhuber M
Handb Exp Pharmacol; 2018; 252():51-67. PubMed ID: 29896655
[TBL] [Abstract][Full Text] [Related]
16. Legal Approaches to New Psychoactive Substances: First Empirical Findings.
van Amsterdam J; Burgess N; van den Brink W
Eur Addict Res; 2023; 29(5):363-372. PubMed ID: 37557091
[TBL] [Abstract][Full Text] [Related]
17. Worldwide legislative challenges related to psychoactive drugs.
Negrei C; Galateanu B; Stan M; Balalau C; Dumitru MLB; Ozcagli E; Fenga C; Kovatsi L; Fragou D; Tsatsakis A
Daru; 2017 Jun; 25(1):14. PubMed ID: 28578694
[TBL] [Abstract][Full Text] [Related]
18. The complex and constantly evolving public health threat of new psychoactive substances in Italy: addressing the main functions of a national observatory of drugs.
Graziano S; Zaami S; Tittarelli R; Pichini S; Sciotti M; Berretta P; Busardò FP; Marinelli E; Tini A; Scaravaggi G; Buscaglia E; Brambilla E; Cavallo M; Locatelli CA; Pacifici R; Varì MR
Ann Ist Super Sanita; 2021; 57(2):144-150. PubMed ID: 34132212
[TBL] [Abstract][Full Text] [Related]
19. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
Grafinger KE; Bernhard W; Weinmann W
Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
[TBL] [Abstract][Full Text] [Related]
20. Impact of insomnia on individual health dissatisfaction in Japan, South Korea, and Taiwan.
Nomura K; Yamaoka K; Nakao M; Yano E
Sleep; 2005 Oct; 28(10):1328-32. PubMed ID: 16295219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
